BridgeBio's Attruby Gains FDA Approval, Challenging Pfizer's Tafamidis in ATTR-CM Treatment on February 23, 2025 Acoramidis Approved ATTR-CM Attruby BridgeBio Cardiomyopathies Pfizer Prealbumin Stabilizer - function tafamidis United States Food and Drug Administration +
Sionna Therapeutics Raises $191 Million in Upsized IPO for Cystic Fibrosis Drug Development on February 08, 2025 Clinical Trials Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator IPO NBD1 Proteins Sionna Stabilizer - function +
Sionna Therapeutics Aims for $150 Million IPO to Advance Cystic Fibrosis Treatments on February 05, 2025 Clinical Trials Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator IPO Nasdaq NBD1 Proteins Sionna Stabilizer - function +